16:08 EDT Bicycle Therapeutics (BCYC) files $500M mixed securities shelf
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics: Strategic Cost Reduction and Program Advancements Justify Buy Rating
- Bicycle Therapeutics Appoints Charles Swanton to Board
- Bicycle Therapeutics reports Q2 EPS ($1.14), consensus (93c)
- Bicycle Therapeutics price target lowered to $25 from $32 at RBC Capital
- Bicycle Therapeutics Approves Proposals at Annual Meeting